drugset
drugset / Trial / NCT03537482

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

NCT03537482 ↗

Phase 0 Recruiting 90 enrolled Ascentage Pharma Group Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.

Timeline

Start
2018-08-07
Primary completion
2024-09-15
Completion
2025-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject APG-2575 Small molecule 20 mg Oral
Subject APG-2575 Small molecule 50 mg Oral
Subject APG-2575 Small molecule 100 mg Oral
Subject APG-2575 Small molecule 200 mg Oral
Subject APG-2575 Small molecule 400 mg Oral
Subject APG-2575 Small molecule 600 mg Oral
Subject APG-2575 Small molecule 800 mg Oral

Indications

hematopoietic and lymphoid cell neoplasm